Blogs about BDX - Stockpickr! Your Source for Stock Ideas

Blogs about BDX

Blogs	Description	Date Updated
Fast Money Recap	Trade Off Merrill Lynch Charlie Gasparino joined the traders to discuss Merrill Lynch (MER). He explained that Merrill announced its raising a lot capital after they said they didn’t need to. The company said Singapore-based Temasek Holdings agreed to buy $3.4 billion of new Merrill shares and Merrill’s management plans to buy 750,000 shares of common stock. Gasparino said the move will dilute shareholders and it goes against what John Thain said he would do a year ago if the brokera...	July 28, 2008
Lower Energy Means Buy Buy Buy	“Despite poor earnings reports, the drop in oil prices is driving the market higher,” Jim Cramer told fans of his “Mad Money” TV show Tuesday. Cramer explained that market players were looking for a major drop in the markets Tuesday after major companies like Apple Computer (AAPL), Texas Instruments (TXN), Sandisk (SNDK) and American Express (AXP) all reported bad numbers. However, the exact opposite happened and the market rallied with the Dow posting triple-digit gains....	July 23, 2008
Jim Cramer's Lightning Round & Sudden Death	Lightning RoundBullishWaste Management (WMI), Dryships (DRYS), Frontline (FRO), Atlas Energy Resources (ATN), Kroger (KR), Safeway (SWY), Terex (TEX), Visa (V), Cepheid (CPHD) and Becton Dickinson (BDX).BearishTeledyne Technologies (TDY).Sudden DeathCramer was bullish on Arch Coal (ACI), Peabody Energy (BTU) and Chesapeake Energy (CHK) and bearish on North American Palladium (PAL) and International Coal Group (ICO)....	May 05, 2008
ThreeB's Portfolio Picks Becton Dickinson and Company	The second stock Cramer gave out as a pick as part of his "ThreeB's Portfolio" was Becton Dickinson and Company (BDX). This, he said, is a "safe" medical device and diagnostics company that makes needles "of all kinds." And with two "smart" acquisitions it recently made, Becton now has an "ultrafast" test to detect drug-resistant staph infections, Cramer said. BDX is up 31% since last July but Jim thinks this has more to go up and investors should consider buying it. Jim is bullish on the compa...	May 01, 2007
Cramer takes a defensive portfolio against Bernanke	Filed under: Analyst reports, Baxter Intl (BAX)On last night's "MAD MONEY" on CNBC, Jim Cramer wanted to show defensive stocks in the medical industrial field. He has seen enough earnings from big companies and he is fed up with the Fed sitting around while the U.S. economy is slowing to a halt. He wants an "Ultimate Defensive Portfolio" of three stocks that are defensive but whose businesses are still growing. He even wanted to take out the companies that are only growing because of foreign bus...	May 01, 2007
Cramer Backs Becton Dickinson (BDX)	Jim Cramer's Second defensive stock on CNBC's MAD MONEY in medical devices as a portfolio of last resort is Becton Dickinson (BDX). It is a safe traditional medical device and diagnostics company. They even invented a longer needle because of Americans getting fatter and needing longer needles. The Genome and Tripath acquisitions are going great and they are into screening for cancer. It is up 31% since he first recommended it in July, but their increased guidance will dr...	April 30, 2007
Cepheid Takeover?	Biosite (BSTE) got a takeover bid from Beckman Coulter (BEC) and Jim immediately started thinking about who may follow in these takeover footsteps. BSTE is a stock Jim recommended on Feb. 23 and he now says to sell the stock. Take profits and buy Cepheid (CPHD) he told us as it will be the "next great diagnostics play." An article in Barron's last week stated that they should probably get a big contract for staph-infection tests in hospitals over Becton Dickinson (BDX). Further if BDX does ge...	March 26, 2007
Cramer's Next Biosite Type Pick	On CNBC's MAD MONEY tonight, Cramer showed where his Biosite (BSTE) that he recommended one month ago has been given a buyout and is up 50%. But what he wants to do is look at what to do now. He said the percentage premium for the buyout what well above the norm. Cramer said you can now look at Cepheid (CPHD). The company tests for staph infection. The other player is Becton-Dickinson (BDX) that he likes a lot and it is up 25% since his recommendation there. I...	March 26, 2007
Cramer's next biotech; plus a CEO benefit-of-the-doubt	Filed under: Analyst reports, Gilead Sciences (GILD), PoliticsOn CNBC's MAD MONEY, Cramer showed where Biosite Inc. (NASDAQ: BSTE) that he recommended one month ago has been given a buyout and is up 50%. But what he wants to do is look at what to do now. He said the percentage premium for the buyout was well above the norm. He said you can now look at Cepheid (NASDAQ: CPHD). The company tests for staph infection. The other player is Becton, Dickinson (NYSE: BDX) and it is up 25% since his recomm...	March 26, 2007

Enter search text here: